Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

Exclusion Criteria

• •Confirmed diagnosis of HAE with nC1-INH or acquired angioedema
• •Patient weighs \<9.5 kg
• •Patient participated in the KVD900-303 trial and withdrew prior to trial completion per the protocol or trial closure
• •Any clinically significant medical condition or medical history that, in the opinion of the Treating Physician, would interfere with the patient's safety.
• •Known hypersensitivity to sebetralstat or its excipients.
• •Patient with a medical history or known to have severe hepatic impairment (Child Pugh C).
• •Patients who require sustained use of strong cytochrome P450 3A4 inhibitors or inducers.